Institute of Cancer & Genetics
Our strategy is to drive research for the benefit of patients affected by cancer and by inherited disease in Wales and beyond, and at all points in the patient pathway - from prevention through screening, diagnosis, imaging, tissue studies, and clinical trials.
The Institute of Cancer & Genetics is a merger of the Institute of Medical Genetics and sections of Oncology, Surgery, Pathology, Haematology, and Gynaecology Oncology.
The Institute of Cancer & Genetics brings together researchers to promote translational research, employing model systems to develop new cancer therapeutics and diagnostics and take them through to the clinic. Covering molecular/cellular biology through to cancer trials there are collaborative links with researchers in the Welsh School of Pharmacy and Cardiff School of Biosciences and also the newly established Cardiff CRUK Cancer Centre. For more information on our research please visit our Cancer Research page.
- May 2013
TRON Study on ITV News
9th May 2013The TRON Study featured in a news article broadcast on ITV recently
Careers in Research Online Survey 2013
7th May 2013Please complete CROS if your primary responsibility is to conduct research and you are employed for this purpose. It should only take about 20 minutes to complete the survey, but …
TRON Clinician Completes Marathon
3rd May 2013Dr Anurag Saxena recently took part in the Virgin London Marathon to raise money for the Tuberous Sclerosis Association.
- TRON Study on ITV News
- April 2013
Philippa Marrack to give the Jonathan Boulter Memorial Lecture 2013 - British Society for Immunology
22nd April 2013The lecture on 9th October, co-organised by the School of Medicine and the British Society for Immunology, will be given by one of the most eminent immunologists in the world.
- Philippa Marrack to give the Jonathan Boulter Memorial Lecture 2013 - British Society for Immunology
- γ-Catenin is expressed throughout normal human hematopoietic development and is required for normal PU.1-dependent monocyte differentiation.
Morgan RG, Liddiard K, Pearn L, Pumford SL, Burnett AK, Darley RL, Tonks A, Leukemia (April 2013)
- Small Molecule Inhibition of p38 MAP Kinase Extends the Replicative Life Span of Human ATR-Seckel Syndrome Fibroblasts.
Tivey HS, Rokicki MJ, Barnacle JR, Rogers MJ, Bagley MC, Kipling D, Davis T, J Gerontol A Biol Sci Med Sci (February 2013)
- γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin.
Morgan RG, Pearn L, Liddiard K, Pumford SL, Burnett AK, Tonks A, Darley RL, Leukemia, Volume 27, 2 (February 2013) pp.336-343
- Deleterious- and disease-allele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing.
Xue Y, Chen Y, Ayub Q, Huang N, Ball EV, Mort M, Phillips AD, Shaw K, Stenson PD, Cooper DN, Tyler-Smith C, 1000 Genomes Project Consortium None, Am J Hum Genet, Volume 91, 6 (December 2012) pp.1022-1032
- Assessment of the potential pathogenicity of missense mutations identified in the GTPase-activating protein (GAP)-related domain of the neurofibromatosis type-1 (NF1) gene.
Thomas L, Richards M, Mort M, Dunlop E, Cooper DN, Upadhyaya M, Hum Mutat, Volume 33, 12 (December 2012) pp.1687-1696